 Bone Density Conservation Agents
"Bone Density Conservation Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
| Descriptor ID |
D050071
|
| MeSH Number(s) |
D27.505.696.242
|
| Concept/Terms |
Antiresorptive Agents- Antiresorptive Agents
- Bone Resorption Inhibitors
- Inhibitors, Bone Resorption
- Resorption Inhibitors, Bone
- Bone Resorption Inhibitory Agents
- Antiresorptive Drugs
|
Below are MeSH descriptors whose meaning is more general than "Bone Density Conservation Agents".
Below are MeSH descriptors whose meaning is more specific than "Bone Density Conservation Agents".
This graph shows the total number of publications written about "Bone Density Conservation Agents" by people in this website by year, and whether "Bone Density Conservation Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 | | 2009 | 0 | 1 | 1 | | 2012 | 2 | 0 | 2 | | 2015 | 0 | 1 | 1 | | 2017 | 3 | 0 | 3 | | 2018 | 0 | 1 | 1 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Bone Density Conservation Agents" by people in Profiles.
-
Liu W, Lee B, Nagamani SCS, Nicol L, Rauch F, Rush ET, Sutton VR, Orwoll E. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta. J Clin Endocrinol Metab. 2023 06 16; 108(7):1787-1796.
-
Azzam KA, Rush ET, Burke BR, Nabower AM, Esposito PW. Mid-term Results of Femoral and Tibial Osteotomies and Fassier-Duval Nailing in Children With Osteogenesis Imperfecta. J Pediatr Orthop. 2018 Jul; 38(6):331-336.
-
Kreikemeier RM, Gosnell H, Halbur LM, Rush ET. A retrospective review of initial bisphosphonate infusion in an inpatient vs. outpatient setting for bisphosphonate na?ve patients. J Pediatr Endocrinol Metab. 2017 Oct 26; 30(10):1105-1110.
-
Khan QJ, Kimler BF, Reddy PS, Sharma P, Klemp JR, Nydegger JL, Yeh HW, Fabian CJ. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial. Breast Cancer Res Treat. 2017 Nov; 166(2):491-500.
-
Webb NJA, Lerner G, Warady BA, Dell KM, Greenbaum LA, Ariceta G, Hoppe B, Linde P, Lee HJ, Eldred A, Dufek MB. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease. Pediatr Nephrol. 2017 Jul; 32(7):1221-1232.
-
Rush ET, Goodwin JL, Braverman NE, Rizzo WB. Low bone mineral density is a common feature of Zellweger spectrum disorders. Mol Genet Metab. 2016 Jan; 117(1):33-7.
-
Winston MJ, Srivastava T, Jarka D, Alon US. Bisphosphonates for pain management in children with benign cartilage tumors. Clin J Pain. 2012 Mar-Apr; 28(3):268-72.
-
Rush ET, DeHaai K, Kreikemeier RM, Lutz RE. Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings. J Pediatr Endocrinol Metab. 2012; 25(5-6):493-7.
-
Srivastava T, Haney CJ, Alon US. Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. J Bone Miner Res. 2009 Feb; 24(2):334-7.
-
Auron A, Tal L, Srivastava T, Alon US. Reversal of hypercalcemic acute kidney injury by treatment with intravenous bisphosphonates. Pediatr Nephrol. 2009 Mar; 24(3):613-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|